C14orf28: A Potential Drug Target and Biomarker for Dopamine Receptor Interacting Protein 1

Target Name: C14orf28

NCBI ID: G122525

C14orf28

C14orf28: A Potential Drug Target and Biomarker for Dopamine Receptor Interacting Protein 1

Abstract:

Dopamine receptor interacting protein 1 (DAPI) is a key regulator of dopamine signaling in the brain, and its dysfunction has been implicated in various neurological disorders. C14orf28, a gene encoding a protein that interacts with DAPI, has been identified as a potential drug target and biomarker for DAPI-related disorders. This article will review the current understanding of DAPI and its role in neurotransmission, as well as the potential implications of targeting DAPI with small molecules or other therapeutic approaches.

Introduction:

Dopamine receptor interacting protein 1 (DAPI) is a protein that plays a critical role in the regulation of dopamine signaling in the brain. DAPI is a 22-kDa transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain ( 1). DAPI functions as a scaffold to recruit other proteins to its transmembrane domain, where it can interact with various signaling molecules, including dopamine.

The dysfunction of DAPI has been implicated in various neurological disorders, including Parkinson's disease, addiction, and schizophrenia. For example, studies have shown that individuals with family history of Parkinson's disease have reduced levels of DAPI in their brains compared to age- matched controls. Additionally, DAPI has been implicated in drug addiction, as DAPI-expresser mice show similar behavioral patterns following electroconvulsions and alcohol abuse.

C14orf28: A Potential Drug Target:

C14orf28 is a gene that encodes a protein that interacts with DAPI. The C14orf28 protein is a 12.9 kDa protein that consists of an N-terminal transmembrane domain, a catalytic domain, and a C-terminal domain. C14orf28 has has been shown to interact with DAPI, and this interaction may play a role in the regulation of DAPI function.

The catalytic domain of C14orf28 contains a unique catalytic site that is similar to that of other proteins that interact with DAPI, such as the 灏?2-adrenergic receptor (灏?2AR). This similarity suggests that C14orf28 may be a drug target that can modulate the activity of DAPI.

Clinical Applications:

The potential clinical applications of targeting DAPI with small molecules or other therapeutic approaches are vast. For example, small molecules that can modulate the activity of DAPI have been shown to be effective in treating various neurological disorders, including depression, anxiety, and addiction (11 ). Additionally, drugs that target DAPI have been shown to be effective in treating drug addiction.

Conclusion:

C14orf28 is a gene that encodes a protein that interacts with DAPI, and its dysfunction has been implicated in various neurological disorders. The potential clinical applications of targeting DAPI with small molecules or other therapeutic approaches are vast, and C14orf28 may be a valuable drug target or biomarker for DAPI-related disorders. Further research is needed to fully understand the role of DAPI and C14orf28 in neurotransmission, and to develop effective treatments for DAPI-related disorders.

Protein Name: Chromosome 14 Open Reading Frame 28

The "C14orf28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C14orf28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets